Sign In
Buy DNA
$7.89
-0.110 (-1.38%)
At Close: Jun 12, 2026
Ferrari has Formula One in its DNA, CEO says after Cadillac supply deal
03:03pm, Tuesday, 10'th Dec 2024
Ferrari Chief Executive Benedetto Vigna said Formula One was in the DNA of the company as earlier on Tuesday it announced it would supply engines and gearboxes to a new Cadillac Formula One team in a
Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better
10:36am, Monday, 18'th Nov 2024
Ginkgo Bioworks reported solid Q3 results, but underlying performance was weaker than the financials suggest after accounting for meaningless non-cash revenue. Ginkgo's new business model focuses on u
Ginkgo Bioworks: Not Enough Progress
08:36am, Wednesday, 13'th Nov 2024
Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost cutting efforts, Ginkgo continues to report large losses, an
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript
10:02pm, Tuesday, 12'th Nov 2024
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q3 2024 Results Conference Call November 12, 2024 5:30 PM ET Company Participants Megan LeDuc - Manager, IR Jason Kelly - Founder, CEO & Director Mark Dmytru
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates
08:00pm, Tuesday, 12'th Nov 2024
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago.
What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company
05:01pm, Tuesday, 12'th Nov 2024
DNA-testing company 23andMe (Nasdaq: ME), once an industry leader that attracted millions of customers, including rapper Snoop Dogg and investor Warren Buffett, has announced significant cuts to its o
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
05:01pm, Tuesday, 12'th Nov 2024
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo
Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing
08:01am, Tuesday, 12'th Nov 2024
BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone o
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
08:30am, Monday, 11'th Nov 2024
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Ac
Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation
07:00am, Tuesday, 05'th Nov 2024
Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON , Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the l
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
07:20pm, Monday, 04'th Nov 2024
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
07:15am, Wednesday, 30'th Oct 2024
STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a re
New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics New l
Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "DNA & RNA Banking Services Market Size, Share and Trends Analysis Report by Service, Specimen (Blood, Buccal Swabs & Hair Follicles, Others), Application
Modifi Biosciences Acquired by Merck
07:05am, Wednesday, 23'rd Oct 2024
Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat ca
